Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.940
Abstract: Ribociclib (KISQALI), a cyclin‐dependent kinase 4/6 inhibitor approved for the first‐line treatment of HR+/HER2– advanced breast cancer with an aromatase inhibitor, is administered with no restrictions on concomitant gastric pH‐elevating agents or food intake. The… read more here.
Keywords: gastric changes; ribociclib bioavailability; food intake;